| Name | Title | Contact Details |
|---|
AveXis, now a Novartis Company, is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and life-threatening neurological genetic d...
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.
We are a biopharmaceutical company focused on accelerating biologics and small molecules through clinical development that have the potential to improve patient lives. We are a team of seasoned pharmaceutical and start-up professionals with an extensive track record of success. Our expertise is in fast, efficient and high quality drug development. Whether developing a reformulated product or a new chemical entity, our management team has expertise to identify regulatory strategies to expedite the path to approval through efficient clinical programs.
ZS Pharma is using innovative technology to change the landscape of disease management. At ZS Pharma, we have a vision—to transform the status quo and improve the options for patients and physicians facing difficult-to-manage conditions such as ion imbalances. We are committed to taking on medicine’s challenges with a new outlook, and we believe that real progress comes with a real promise to approach things in a novel way.